Nick is a clinical and laboratory haematologist at Alfred Health, completing a PhD with the Myeloma Research Group at the Australian Centre for Blood Diseases. His PhD examines extramedullary myeloma using next generation sequencing techniques to identify therapeutic opportunities and clinical applications in this high risk patient cohort.

Dr. Mithraprabhu is a Research Fellow at the Australian Centre for Blood Diseases - Monash University based at the Alfred Hospital. She is lead for the liquid biopsy research program in the Myeloma Research Group.

Adam D. Cohen, MD, is the Director of Myeloma Immunotherapy, Amyloidosis Program Co-Director, and Associate Professor of Medicine at the Abramson Cancer Center at the University of Pennsylvania. His research focuses on clinical development of novel therapies, particularly immunotherapies, for patients with myeloma, AL amyloidosis and other plasma cell dyscrasias.

James Rowland is a final year haematology advanced trainee at the Princess Alexandra Hospital in Queensland. He has a keen clinical and research interest in amyloidosis and has completed significant work on the implementation of a novel laser microdissection with tandem mass spectrometry assay within Pathology Queensland.

Dr Anthea Gibbons is a Medical Registrar with a keen interest in the discipline of haematology.

Eric is a clinical and molecular pathology fellow at the Royal Prince Alfred Hospital. His interest is in malignant haematology. He enjoys collaborative work and is proactive in Young Blood, an organisation that provides education and career development events for advanced trainees in NSW.